JAZZ Q1 2023 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena

JAZZJazz Pharmaceuticals plc

$12B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$893M+9.7% YoY

Gross Profit

$764M85.6% margin

Operating Income

$126M14.1% margin

Net Income

$69M7.8% margin

EPS (Diluted)

$1.04

QoQ Revenue Growth

-8.2%

Cash Flow

Operating Cash Flow

$321M

Free Cash Flow

$317M

Stock-Based Comp.

$56M

Balance Sheet

Total Assets

$11.0B

Total Liabilities

$7.7B

Stockholders' Equity

$3.3B

Cash & Equivalents

$1.2B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$893M	$814M	+9.7%
Gross Profit	$764M	$698M	+9.4%
Operating Income	$126M	$88M	+44.0%
Net Income	$69M	$2M	+4114.9%

Revenue Segments

Xywav

$278M31%

Epidiolex/Epidyolex

$189M21%

Xyrem

$178M20%

Rylaze/Enrylaze

$86M10%

Zepzelca

$67M8%

Defitelio/Defibrotide

$39M4%

Vyxeos

$37M4%

Sativex

$7M1%

Other Royalty And Contract Revenues

$6M1%

Other Products

$3M0%

High Sodium AG Oxybate Product Royalty Revenue

$2M0%

Geographic Segments

UNITED STATES

$810M91%

Europe

$66M7%

Other Countries

$17M2%